GleamWall
中文EN

MCRB Seres Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%

Returns

ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$593,000$736,000$358,000$438,000$351,000$0$0$0
R&D expense$5.59M$9.14M$13.20M$11.68M$12.62M$12.94M$11.82M$12.84M
SG&A expense$5.45M$7.06M$8.07M$7.54M$9.48M$10.25M$11.89M$12.46M
Operating income-$16.15M-$21.27M-$20.91M-$19.38M-$22.48M-$24.88M-$27.24M-$28.84M
Interest expense—————$0$0$0
Income tax$0$0$0$0$0$0$0$0
Net income-$16.29M$4.58M-$19.91M-$15.34M$8.20M-$19.86M$32.68M-$15.64M
EBITDA-$15.67M-$20.60M-$20.13M-$18.42M-$21.43M-$23.82M-$26.16M-$27.75M
EPS (basic)-1.630.47-2.08—0.94-2.273.76—
EPS (diluted)-1.630.47-2.08—0.94-2.273.75—
Weighted avg. shares (diluted)9.98M9.75M9.58M—8.77M8.74M8.71M—
Balance sheet
Cash & equivalents$17.53M$15.59M$29.83M$45.77M$56.31M$54.05M$67.52M$39.46M
Receivables$183,000$274,000$233,000$157,000$351,000——$0
Current assets$34.42M$42.35M$31.84M$49.38M$51.53M$48.69M$66.08M$38.67M
PP&E, net$3.00M$5.80M$6.85M$7.63M$8.58M$9.62M$10.55M$11.53M
Total assets$65.89M$101.59M$117.62M$138.19M$143.47M$143.80M$164.18M$139.81M
Current liabilities$20.89M$20.03M$19.34M$19.32M$22.43M$30.94M$31.32M$41.22M
Total liabilities$44.53M$67.05M$91.12M$93.97M$99.78M$110.85M$113.72M$126.03M
Shareholders' equity$21.36M$34.53M$26.50M$44.22M$43.70M$32.95M$50.47M$13.78M
Shares outstanding10.05M9.83M9.59M9.56M8.76M8.75M8.73M8.65M
Cash flow statement
Operating cash flow-$10.48M-$22.39M-$16.36M-$14.71M$2.21M-$13.29M$26.91M-$38.88M
Capital expenditure$0$0$0$29,000$8,000$181,000$34,000$90,000
Free cash flow-$10.48M-$22.39M-$16.36M-$14.74M$2.20M-$13.47M$26.88M-$38.97M
Investing cash flow$12.55M$14,000$0$181,000-$8,000-$181,000-$34,000-$90,000
Financing cash flow$752,000$1.72M$428,000$12.66M$61,000$0$1.18M$1.74M
Depreciation & amortization$481,000$670,000$781,000$954,000$1.04M$1.06M$1.08M$1.08M
Stock-based compensation$1.86M$1.74M$1.77M$3.20M$2.48M$2.34M$2.82M$3.77M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.